|
Malignant Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, we also confirmed that IFN-β suppressed the acquisition process of undifferentiated features in human malignant glioma cell lines.
|
26397698 |
2015 |
|
Malignant Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Arginine modified PAMAM dendrimer for interferon beta gene delivery to malignant glioma.
|
23384727 |
2013 |
|
Malignant Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated whether IFN-β inhibits the growth of human malignant glioma and induces glioma cell apoptosis using the human IFN-β gene transfected into glioma cells.
|
22938469 |
2012 |
|
Malignant Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We present a list of the most highly upregulated and downregulated genes which may be involved in conferring a response to IFN-β and synergistic effect between IFN-β and TMZ in malignant gliomas.
|
21805051 |
2011 |
|
Malignant Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In our pilot clinical trial in glioma, the IFN-beta gene has shown potent antitumor activity in patients with malignant glioma.
|
19893595 |
2010 |
|
Malignant Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that the clinical therapeutic efficacy of TMZ might be improved by a combination with IFN-beta in malignant gliomas unmethylated at the MGMT gene.
|
19513561 |
2009 |
|
Malignant Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In an effort to improve the therapeutic index of IFN-beta by providing local, sustained delivery of IFN-beta to gliomas, the safety and biological activity of a human IFN-beta (hIFN-beta)-expressing adenovirus vector (Ad.hIFN-beta) was evaluated in patients with malignant glioma by stereotactic injection, followed 4-8 days later by surgical removal of tumor with additional injections of Ad.hIFN-beta into the tumor bed.
|
18180770 |
2008 |
|
Malignant Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have previously performed a pilot clinical trial to evaluate the safety and effectiveness of this IFN-beta gene therapy in five patients with high-grade glioma.
|
18220319 |
2008 |
|
Malignant Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thereafter, we performed a pilot clinical trial in patients with malignant glioma and confirmed the safety and effectiveness of this interferon-beta gene therapy.
|
15546502 |
2004 |
|
Malignant Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study suggests the feasibility and safety of interferon beta gene therapy, which may become an important treatment option for patients with malignant glioma.
|
14965379 |
2004 |
|
Malignant Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on these results, we performed three different antiangiogenic experiments targeted to inhibit VEGF expression in a human malignant glioma (U87) mouse model: anti-VEGF neutralized antibody intraperitoneal injection; interferon-beta intramusclar injection; and transfection of an endogenous nonspecific angiogenesis inhibitor, thrombospondin-1, into glioma cells caused inhibition of VEGF secretion and/or mRNA expression and resulted in glioma growth inhibition of 70%, 84%, and 50%, respectively, compared with control.
|
15700836 |
2004 |
|
Malignant Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma.
|
10982152 |
2000 |
|
Malignant Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Human malignant gliomas (glioblastomas and anaplastic astrocytomas) are the most frequent brain tumors and are associated with a variety of genetic alterations including retinoblastoma (RB) and p53 gene mutations, loss of interferon alpha and beta (IFNA, IFNB) genes and lack of O6-methylguanine-DNA methyltransferase (MGMT) expression.
|
1501894 |
1992 |